Literature DB >> 25647441

Cluster-Randomized Trial of Clinical Pharmacist Tobacco Cessation Counseling Among Patients with Cardiovascular Disease.

Jody Adams1, Alicia A Cymbala2,3, Thomas Delate2,3, Deanna Kurz2, Kari L Olson2,3, Morgan Youngblood2,3, Emily Zadvorny2,3,4.   

Abstract

Optimal management of patients with cardiovascular disease (CVD) includes evaluation of risk factors using a team-based approach. Tobacco use often receives less attention than other CVD risk factors; therefore, utilization of nonphysician health care providers may be valuable in addressing tobacco use. The purpose of this trial was to assess the impact of brief, structured, telephone tobacco cessation counseling (BST) delivered by clinical pharmacists on tobacco cessation attempts compared to usual care. The BST consisted of 1 to 5 minutes discussing 3 key counseling points, including a recommendation to quit and education about cessation aids. This was a cluster-randomized trial of tobacco-using patients with CVD who were enrolled in a clinical pharmacist-managed, physician-directed, CVD disease state management service. Clinical pharmacists were randomized to provide usual care (control) or BST (intervention) to their tobacco-using patients during a 4-month period. Patients were surveyed 3 months later to assess their tobacco cessation attempts, use of tobacco cessation aids, and self-reported cessation. One hundred twenty patients were enrolled. Subjects were predominately white males, aged ≥65 years, with a history of myocardial infarction. One hundred and four subjects completed the follow-up survey. No differences were detected between the 36.2% and 38.6% of control and intervention subjects, respectively, reporting a tobacco cessation attempt (P=0.804) or in the other outcomes (all P>0.05). A BST delivered by clinical pharmacists may not adequately affect patient motivation enough to increase tobacco cessation attempts in tobacco-dependent patients with CVD. Future research is needed to evaluate other team-based strategies that can decrease tobacco use in patients with CVD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25647441     DOI: 10.1089/pop.2014.0106

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  4 in total

Review 1.  Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice.

Authors:  Chris Gibbons; Ian Porter; Daniela C Gonçalves-Bradley; Stanimir Stoilov; Ignacio Ricci-Cabello; Elena Tsangaris; Jaheeda Gangannagaripalli; Antoinette Davey; Elizabeth J Gibbons; Anna Kotzeva; Jonathan Evans; Philip J van der Wees; Evangelos Kontopantelis; Joanne Greenhalgh; Peter Bower; Jordi Alonso; Jose M Valderas
Journal:  Cochrane Database Syst Rev       Date:  2021-10-12

2.  Development of a Pharmacist-Led Opt-Out Cessation Treatment Protocol for Combustible Tobacco Smoking Within Inpatient Settings.

Authors:  Philip J Trapskin; Ann Sheehy; Paul D Creswell; Danielle E McCarthy; Amy Skora; Rob T Adsit; Anne E Rose; Candace Bishop; Jessica Bugg; Emily Iglar; Mark E Zehner; Daniel Shirley; Brian S Williams; Adam J Hood; Krista McElray; Timothy B Baker; Michael C Fiore
Journal:  Hosp Pharm       Date:  2021-03-05

3.  Can inpatient pharmacists move the needle on smoking cessation? Evaluating reach and representativeness of a pharmacist-led opt-out smoking cessation intervention protocol for hospital settings.

Authors:  Paul D Creswell; Danielle E McCarthy; Philip Trapskin; Ann Sheehy; Amy Skora; Robert T Adsit; Mark E Zehner; Timothy B Baker; Michael C Fiore
Journal:  Am J Health Syst Pharm       Date:  2022-06-07       Impact factor: 2.980

Review 4.  Digital Health Interventions by Clinical Pharmacists: A Systematic Review.

Authors:  Taehwan Park; Jagannath Muzumdar; Hyemin Kim
Journal:  Int J Environ Res Public Health       Date:  2022-01-04       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.